BBC
Virtus LifeSci Biotech Clinical Trials ETF
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 33.9 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Inception date | Dec 16, 2014 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| OMEROS CORP | 1.4 % |
| UNIQURE N.V. | 1.0 % |
| REZOLUTE INC | 1.0 % |
| KODIAK SCIENCES, INC. | 1.0 % |
| TYRA BIOSCIENCE, INC | 1.0 % |
| INTREXON CORP | 0.9 % |
| BELITE BIO INC ADR | 0.9 % |
| EYEPOINT PHARMACEUTICALS INC | 0.9 % |
| CAPRICOR THERAPEUTICS, INC. | 0.9 % |
| SEPTERNA INC | 0.9 % |
Constituent Breakdown
| Number of holdings | 128 |
| Herfindahl-Hirschman Index | 81 |
| Wgt avg mkt cap (mns) | $1,513 |
| Large cap (>$10bn) | 1.6% |
| Mid cap ($2-10bn) | 19.1% |
| Small cap (<$2bn) | 57.4% |
| Developed mkts. | 81.5% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 76.6 % |
 |
GERMANY | 1.6 % |
 |
CANADA | 1.6 % |
 |
NETHERLANDS | 1.0 % |
 |
SINGAPORE | 0.8 % |
 |
IRELAND | 0.8 % |
 |
SWITZERLAND | 0.7 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 10.1% | 108.8% | 18.8% | 19.3% | -4.8% | 9.4% | -- | 4.2% |
| Dividend Yield | 0.0% | 3.5% | 1.6% | 1.2% | 0.6% | 0.5% | -- | 0.4% |
| Total Returns | 10.1% | 112.3% | 20.4% | 20.5% | -4.2% | 9.9% | -- | 4.7% | Ann. Volatility | 37.8% | 40.7% | 37.7% | 36.4% | 39.5% | 38.1% | -- | 38.7% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.04 | 24% |
| MSCI EAFE | 1.14 | 21% |
| MSCI Emg Mkts | 1.00 | 20% |
Liquidity Measures
| Avg. volume (000) | 19 |
| ADV traded (mns) | $1 |
| Turnover | 2.2% |
| Avg. Bid/Ask (% of price) | 0.24% |
Technical Indicators
| 30d moving avg. (EMA) | $41.19 |
| Relative strength (RSI) | 48 |
| MACD/Signal | -0.22/0.11 |
| Bollinger Bands (Upper/Lower) | $43.77/$39.65 |
| Short interest (% of AUM) | 3.3% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BBC |
Expenses vs. BBC |
ALTAR Score™ vs. BBC |
|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 32.6% | -44 bp | +0.4% |
| SBIO | ALPS Medical Breakthroughs ETF | 28.8% | -29 bp | 0.0% |
| CANC | Tema Oncology ETF | 17.4% | -4 bp | -2.1% |
| FMED | Fidelity Disruptive Medicine ETF | 12.1% | -29 bp | -1.3% |
| IBB | iShares Biotechnology ETF | 11.9% | -34 bp | -0.6% |
| IWC | iShares Micro-Cap ETF | 11.7% | -19 bp | -1.2% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 10.4% | -60 bp | +0.3% |
Risk and Returns: BBC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 3/23/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 1,188 funds in the US Equity category with an average
ALTAR Score™ of 5.8% and a standard deviation
of 2.1%. BBC's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places BBC in the percentile
among funds in the category.
Sell-Side Consensus
$60.82
PRICE TARGET
+53.6%
UPSIDE